Durability of Sustained Virologic response in patients with Chronic Hepatitis c after treatment With Interferon 2b Alone or in Combination with Ribavirin

Impact of Pegylated Interferon alfa-2b (Peg-Intron) and Ribavirin on Progression of Liver Fibrosis in patients with Chronic Hepatitis C

Abstract 676. ACUTE HEPATITIS C: NATURAL COURSE AND RESPONSE TO ANTIVIRAL TREATMENT

HALT-C Trial: 4-year study of Maintenance Therapy in 1350 patients

Pegylated interferon alfa/ribavirin in persons who failed to prior interferon based therapy

Hepatitis B Therapy at AASLD

HCV Viral Load Ultrasensitive Testing

How Often Should You Do a Liver Biopsy?

Interferon Improves Risk for Death and Cancer

New Hepatitis B Drugs

HCV Therapy in HCV/HIV Coinfection

OPEN-LABEL PHASE 1B STUDY OF HEPATITIS C VIRAL DYNAMICS WITH OMEGA INTERFERON TREATMENT

HCV Therapy Adherence; New drugs

EFFECT OF INTERFERON THERAPY ON THE RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C: A LARGE RETROSPECTIVE COHORT STUDY OF 3296 PATIENTS

Menopause May Accelerate Liver Fibrosis; Perhaps Hormone Replacement Therapy Can Be Helpful

SEN Virus Variants Are "Unequivocally Transmitted By Blood Transfusion" in the US

Treatment of Chronic Hepatitis C

New HCV Drug in Phase I
Idun Pharmaceuticals' Clinical Trial

Rivarin-High Dose Interferon Combination Improves Responses In Hepatitis C

Sweden Approves Expanded Use of Naturally-Derived Alpha Interferon

Phase II Trial of ISIS 14803 for Hepatitis C Getting Underway

On Page Two:

Research Articles 2002 & 2003 Always Updated

Page Three:

HCV Highlights from DDW 2002 (New)

Page Four

Reports from Digestive Disease Week 2003: Orlando Fla, May 17-22